All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub

Brought to you by Scientific Education Support

Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My AML Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View AML content recommended for you

EHA 2022

Share:

Jun 8, 2022

X post image

22 Oct 2022

📚Weekend Re-read:
Take a look at the first results from the phase III QuANTUM-First trial and the OS in adults aged 18–75 with newly diagnosed FLT3-ITD+ #AML. https://t.co/1jqIONZ3LE #AMLsm #leusm #EHA2022

X post image

19 Aug 2022

At #EHA2022 @MusaYilmazMD presented updated data on the combination of quizartinib, decitabine, and venetoclax in heavily pretreated FLT3-mutant #AML. Read our summary here:
👉 https://t.co/SmjPAIOcm0 👈
#AMLsm #leukemia #leusm

X post image

18 Aug 2022

At #EHA2022 @MusaYilmazMD presented updated data on the combination of quizartinib, decitabine, and venetoclax in heavily pretreated FLT3-mutant #AML. Read our summary here:
👉 https://t.co/SmjPAIOcm0 👈
#AMLsm #leukemia #leusm

X post image

10 Aug 2022

💬 @GOssenkoppele begins by introducing the study presented #EHA2022, outlining the study design and trial results. He then highlights OS, and feasibility of this therapy as a bridge to allogeneic transplant

👉 https://t.co/mHqVJ5dkgu 👈

#AMLsm #leusm #leukemia

X post image

6 Aug 2022

💬 During #EHA2022 Congress, the AML Hub spoke with Isolda Fernandez, @Fundaleu. We asked, What is the clinical significance of secondary-AML-type mutations in de novo #AML

👉 https://t.co/3cwbuyoYBg 👈

#leusm #leukemia #AMLsm @Isoldafernande1

X post image

5 Aug 2022

📹 During #EHA2022, the AML Hub spoke with Brian Huntly, @Cambridge_Uni We asked, What is the clinical significance of co-mutational patterns in #AML?

👉 https://t.co/vebd3yinm0 👈

#leusm #leukemia #AMLsm

X post image

19 Jul 2022

Check out the first results from the phase III QuANTUM-First trial. Compared to placebo, quizartinib + chemotherapy & up to 3 years of continuation therapy significantly improved OS in adults aged 18–75 with ND FLT3-ITD+ #AML

⭐ https://t.co/1jqIONYvW6 ⭐

#AMLsm #leusm #EHA2022

X post image

8 Jul 2022

👀 During #ASCO2022, the AML Hub spoke with
@Daver_Leukemia, @MDAndersonNews. We asked, about the latest updates from #EHA2022 on magrolimab in TP53-mutated #AML and #MDS.

#leusm #AMLsm #leukemia

X post image

28 Jun 2022

📊 Updated results from the QUAZAR AML-001 trial were presented at #EHA2022 by Andrew Wei et al.—oral azacitidine maintenance leads to more patients achieving long-term survival versus placebo.

👉 https://t.co/MwLFnHGaSf 👈

#AML #leusm #AMLsm #leukemia

X post image

21 Jun 2022

📢For all our #EHA2022 live coverage check out our twitter moments! And keep an eye out for further articles and videos on the AML Hub!

#leusm #leukemia #AMLsm

https://t.co/TlaLBENhAn

X post image

12 Jun 2022

We hope you’ve enjoyed keeping up with our live #EHA2022 congress updates! 🎓

Keep an eye on our socials for post-congress summaries and key insights! 📲

#EHA2022 #medicalcongress #cancerawareness

X post image

12 Jun 2022

Congress| #EHA2022 @nagler_EBMT, @sheba_medical discusses allocating the best donor for HSCT in #AML pts achieving CR1 after 2 inductions, comparing matched related against unrelated against haploidentical donors #leusm #medicalcongress

X post image

12 Jun 2022

Congress| #EHA2022 Dr Magnus Tobiasson, Karolinska University Hospital evaluates the potential of residual disease markers as a prediction of relapse after ASCT. He highlights that MRD used as a time-dependent co-variate was -ve associated with RFS #AML #leusm #medicalcongress

X post image

12 Jun 2022

It’s the last day of EHA!
Don’t miss out on closing interviews, key insights, and live updates!
Session covered👇
- Clinical studies in transplantation

#EHA2022 #medicalcongress #cancerawareness

X post image

11 Jun 2022

#EHA2022 | CR/CRh rate, 40% in spliceosome mutated R/R #AML and 33% in FLT3m R/R AML

#leusm

X post image

11 Jun 2022

CONGRESS | #EHA2022 | Gullermo Garcia-Manero, @MDAndersonNews, presented the safety and clinical activity of emavusertib as monotherapy or in combination with AZA or VEN. No DLTs were observed at 200 mg and 300 mg BID #leusm #AML

X post image

11 Jun 2022

#EHA2022 | CPX-351 did not improve OS or EFS compared to FLAG-Ida
CPX-351 was associated with superior 3-year RFS (39% vs 29%), possibly driven by a higher number of patients proceeding to transplant #leusm #AML

X post image

11 Jun 2022

CONGRESS | #EHA2022 | Nigel Russell, @GSTTnhs, compared CPX-351 with FLAG-Ida in a randomised trial for pts in patients with HR #AML. #Leusm

X post image

11 Jun 2022

#EHA2022 | In the R/R cohort, median 0S was 6.9m and with 14.5mo for the ND cohort #leusm #AML

X post image

11 Jun 2022

CONGRESS | #EHA2022 | Musa Yilmaz, @MDAndersonNews, presented phase I/II data on DAC + VEN + QUIZ triplet in pts with FLT3-ITDm #AML. 23/28 pts with R/R AML achieved CRc and all 7 pts with ND AML achieved CRc. Pts with underlying RAS/MAPK mutations had lower response rates #leusm

X post image

11 Jun 2022

#EHA2022 | Nigel Russell, @GSTTnhs assessed the safety of midostaurin + GO & intensive induction therapy in FLT3m #AML. CR was achieved in 51/59 (88%) evaluable pts who completed induction w/ GO at a single dose. Dose interruption for QTc prolongation occurred in 2 pts. #leusm

X post image

11 Jun 2022

#EHA2022 | DAC was associated with a more favourable safety profile particularly in relation to GI disorders, and produced superior health economics #leusm #aml

X post image

11 Jun 2022

CONGRESS | #EHA2022 | Michael Lübbert, @UniFreiburg, compared 10-day DAC vs 3+7 chemo followed by allo-HSCT in ND or untreated sAML. No significant difference in OS and PFS was reported, but younger pts and NPM1m #AML benefit more from 3+7 #leusm

X post image

11 Jun 2022

#EHA2022 | Finally, Daver discussed treating TP53m #AML, focusing on immune based combination approaches, including magrolimab + AZA ∓ VEN and whether a doublet or triplet therapy is optimal #leusm

X post image

11 Jun 2022

#EHA2022 | @Daver_Leukemia also outlined treatment in IDHm #AML, discussing improved OS with AZA + ivosidenib in IDH1 mutated AML and the potential to switch between HMA + VEN and this doublet regimen when pts relapse

X post image

11 Jun 2022

#EHA2022 | Frontline triplet combinations improve response in FLT3m #AML, but monitoring of prolonged myelosuppression is needed
Shorter durations of VEN in these regimens may improve count recovery
#leusm

X post image

11 Jun 2022

#EHA2022 | Daver discussed how to target each molecular subgroup, beginning with FLT3 mutated #AML, and how a combination of Gilteritinib and VEN improves transition to allo-HSCT #leusm

X post image

11 Jun 2022

#EHA2022 | @Daver_Leukemia, @LeukemiaMDA, regimens of VEN + AZA ∓ targeted therapies in harder to treat #AML, and firstly analysed which subgroups of pts do not respond well to VEN + AZA treatment #leusm

X post image

11 Jun 2022

We will be bringing you live updates during our live coverage of @EHA_Hematology congress!

Sessions covered today: AML in the elderly unfit patients, precision medicine in AML and novel insights in AML treatment

#EHA2022 #medicalcongress #cancerawareness

X post image

11 Jun 2022

#EHA2022 | Bullinger outlined the outlook for elderly #AML, including new technology to study chromatin interactions and how mutational patterns impact chromosomal rearrangements in high detail, and using single cell techniques to study the microenvironment #leusm

X post image

11 Jun 2022

#EHA2022 | TP53 mutations are associated with worsened response to HMA treatment, which is not improved with the addition of venetoclax #AML #leusm

X post image

11 Jun 2022

#EHA2022 | Study data demonstrates that mutational patterns changes as early as 50 years old and is not restricted to pts ≥ 65 years
The mutational pattern linked to older age is associated with worse survival outcomes in ND and NPM1m #AML #leusm

X post image

11 Jun 2022

#EHA2022 | Lars Bullinger, @uni_ulm summarised the molecular landscape of elderly #AML, firstly highlighting an increased number of high-risk gene and chromosomal aberrations, including TP53 and spliceosome mutations, with age, making the disease more complex to treat #leusm

X post image

10 Jun 2022

Congress| #EHA2022 Karin Huber, Universitätsklinikum Heidelberg evaluates the role of LPIN1 in #AML and healthy hematopoietic cells. He highlights LPIN1 is key in maintaining lipid homeostasis and stem cell function and could help refine targeted therapies #leusm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Prof Christian Thiede, Medizinische Klinik und Poliklinik discusses NGS-based minimal residual disease detection in peripheral blood in the context of the UNIFY trial. #AML #leusm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Stephane De Botton, @GustaveRoussy evaluates the impact of ivosidenib and azacitidine on IDH1-mutation clearance and baseline co-mutation analysis from the AGILE trial #AML #leusm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 @drsangeetmd, @MDAndersonNews discusses low intensity frontline therapy for pts with #AML. The regimen produced high rates of response, encouraging EFS, OS, and low early mortality in pts predicted to have high risk of early death #leusm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Tim Grob, Erasmus Medical Center evaluates the use of NGS-based FLT3-ITD MRD detection on treatment outcomes in #AML pts. NGS results identify a profound risk of relapse and death that out compete most accepted prognostic factors #AMLsm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Esperanza Martín-Sánchez, @ClinicaNavarra evaluates the use of immune biomarkers to predict SARS CoV 2 vaccine effectiveness in pts with haematological malignancies #AML #AMLsm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Prof Jianxiang Wang, Chinese Academy of Medical Sciences evaluates the efficacy and safety of gilteritinib vs SC in Asian pts with R/R FLT3mut #AML after first-line therapy. He highlights Gilteritinib significantly prolonged OS/EFS vs SC #AMLsm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Gianluca Cristiano, University of Bologna evaluates the predictive value of lymph count recovery in #AML pts. She highlights that ALC consolidation therapy recovery showed a statistically significant association with better OS and LFS #AMLsm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Yannik Severin, @IMSB_ETH discusses how maturation-associated intra-tumor drug response heterogeneity is a strong predictor of clinical response to first-line intensive induction chemotherapy in #AML #AMlsm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Ruihao Huang, Xinqiao Hospital of Army Medical University evaluates the safety and primary efficacy of CD33 CAR NK cells in r/r #AML. He highlights that 4 of 5 patients received MRD negative CR at day 28 assessment #AMLsm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 @Daver_Leukemia, @MDAndersonNews reports on tolerability and efficacy data from a phase 1b trial of magrolimab + AZA in pts with TP53mut #AML unsuitable for intensive chemotherapy. Results showed good responses and encouraging OS #AMLsm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Kuojui Sun, National Taiwan University shows #AML patients with sAML-type mutations have distinct clinical features and poorer outcomes, highlighting that incorporating sAML-type mutations can help refine the 2017 ELN risk stratification #AMLsm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 Alberto Hernández-Sánchez, Hospital Universitario de Salamanca proposes a new genetic stratification model for NPM1mut #AML that identifies 3 groups with different OS/RFS, improving ELN2017 criteria after reclassifying 33% of patients #AMLsm #medicalcongress

X post image

10 Jun 2022

Congress| #EHA2022 @FirasElChaer, @UVA discusses treatment options with anthracyclines at standard dosing, higher dosing and fractionated with Gemtuzumab ozogamicin for favourable risk #AML pts. He highlights no differences in RFS or OS #AMLsm #medicalcongress

X post image

10 Jun 2022

The AML Hub will be covering the following session/s today virtually (&/or) in-person:

Novel treatment options and prognostic markers in AML

Stay tuned for live updates, key insights, and interview coverage!

#EHA2022 #medicalcongress #cancerawareness

X post image

7 Jun 2022

The @AML_Hub will be covering the EHA 2022 Congress!

The first ever hybrid @EHA_Hematology congress, where we will be attending online and in Vienna!

Keep an eye on our socials for live updates throughout the day! 🗣💻

#EHA2022 #medicalcongress #cancerawareness

X post image

6 Jun 2022

To help navigate the exciting content being presented at the #EHA2022 Congress, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in #AML. Check it out here 👇

https://t.co/znQiYrIY2J

X post image

13 May 2022

🚨 N E W S 🚨

Primary endpoint met in phase 3 trial, ASCERTAIN. Investigating the oral hypomethylating agents decitabine and cedazurine. Further data will be presented at #EHA2022 in June!

#AML #AMLsm #leusm #leukemia

pan> </span

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2022 European Hematology Association

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Clinical trials in AML - match patients with relevant trials

Newsletter

Subscribe to get the best content delivered to your inbox